WO2001064031A3 - Slpi knockout mice and methods for wound treatment - Google Patents

Slpi knockout mice and methods for wound treatment Download PDF

Info

Publication number
WO2001064031A3
WO2001064031A3 PCT/US2001/006675 US0106675W WO0164031A3 WO 2001064031 A3 WO2001064031 A3 WO 2001064031A3 US 0106675 W US0106675 W US 0106675W WO 0164031 A3 WO0164031 A3 WO 0164031A3
Authority
WO
WIPO (PCT)
Prior art keywords
slpi
human animal
transgenic non
methods
provides
Prior art date
Application number
PCT/US2001/006675
Other languages
French (fr)
Other versions
WO2001064031A2 (en
Inventor
Sharon M Wahl
Gillian S Ashcroft
Ke-Jian Lei
Original Assignee
Us Health
Sharon M Wahl
Gillian S Ashcroft
Lei Ke Jian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Sharon M Wahl, Gillian S Ashcroft, Lei Ke Jian filed Critical Us Health
Priority to AU2001241913A priority Critical patent/AU2001241913A1/en
Publication of WO2001064031A2 publication Critical patent/WO2001064031A2/en
Publication of WO2001064031A3 publication Critical patent/WO2001064031A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)

Abstract

The invention provides a transgenic non-human animal having a functional disruption in an endogenous SLPI gene. According to the invention, the disruption results in impaired wound healing, reduced defense to pathogens, pathogenic response to antigen induced asthma, or a pathogenic inflammatory response. The invention also provides methods for making the transgenic non-human animal. The transgenic non-human animal can be used as a model for disease states including inflammation, for example, asthma, wound healing, etc. and to screen for therapeutic agents for treating the same. The invention also provides a method for treating inflammation, by administering SLPI peptide.
PCT/US2001/006675 2000-03-01 2001-03-01 Slpi knockout mice and methods for wound treatment WO2001064031A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001241913A AU2001241913A1 (en) 2000-03-01 2001-03-01 Methods for wound treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18610000P 2000-03-01 2000-03-01
US60/186,100 2000-03-01

Publications (2)

Publication Number Publication Date
WO2001064031A2 WO2001064031A2 (en) 2001-09-07
WO2001064031A3 true WO2001064031A3 (en) 2002-05-10

Family

ID=22683657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006675 WO2001064031A2 (en) 2000-03-01 2001-03-01 Slpi knockout mice and methods for wound treatment

Country Status (2)

Country Link
AU (1) AU2001241913A1 (en)
WO (1) WO2001064031A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0309064D0 (en) 2003-04-22 2003-05-28 Univ Manchester Modified peptides and their uses
EP1732593A1 (en) * 2004-03-31 2006-12-20 Coloplast A/S Use of epi-hne 1-4

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346500A1 (en) * 1987-12-28 1989-12-20 Teijin Limited Elastase inhibiting polypeptides and process for their preparation by genetic recombination
EP0402068A1 (en) * 1989-06-09 1990-12-12 Zeneca Limited Polypeptides and polypeptide analogues with inhibitory activity against human elastase
WO1992006706A1 (en) * 1990-10-16 1992-04-30 John Lezdey Treatment of inflammation
WO1999017800A1 (en) * 1997-10-03 1999-04-15 Amgen Inc. Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
WO2001030389A1 (en) * 1999-10-26 2001-05-03 Japan Tissue Engineering Co., Ltd. Wound contraction inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
EP0346500A1 (en) * 1987-12-28 1989-12-20 Teijin Limited Elastase inhibiting polypeptides and process for their preparation by genetic recombination
EP0402068A1 (en) * 1989-06-09 1990-12-12 Zeneca Limited Polypeptides and polypeptide analogues with inhibitory activity against human elastase
WO1992006706A1 (en) * 1990-10-16 1992-04-30 John Lezdey Treatment of inflammation
WO1999017800A1 (en) * 1997-10-03 1999-04-15 Amgen Inc. Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
WO2001030389A1 (en) * 1999-10-26 2001-05-03 Japan Tissue Engineering Co., Ltd. Wound contraction inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASHCROFT G S ET AL: "SECRETORY LEUKOCYTE PROTEASE INHIBITOR MEDIATES NON-REDUNDANT FUNCTIONS NECESSARY FOR NORMAL WOUND HEALING", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 6, no. 10, October 2000 (2000-10-01), pages 1147 - 1148,1150-1153, XP002937064, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
WO2001064031A2 (en) 2001-09-07
AU2001241913A1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
CY1108211T1 (en) Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with monosaccharide-based compounds
WO2001089457A3 (en) Thrombopoietin mimetics
DE60227658D1 (en) METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE, PSYCHIATRIC AND OTHER DISORDERS WITH DEACETYLASEINHIBITORS
ATE472325T1 (en) INTRACORPORAL MEDICATIONS FOR THE PHOTODYNAMIC TREATMENT OF DISEASES
WO2000078332A3 (en) Fish serine proteinases and their pharmaceutical and cosmetic use
ATE280496T1 (en) METHOD FOR TREATING ASTHMA USING O-DESULFATIZED HEPARIN
WO2003034995A3 (en) Integrin targeting compounds
WO2005004793A3 (en) Compositions and methods for treating coagulation related disorders
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
MXPA03000188A (en) Methods of treating neutrophil-related diseases with topical anesthetics.
WO2007014943A3 (en) Therapy for neurological diseases
DE60131393D1 (en) METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ACUTE INFLAMMATION UNDER NON-AMERICAN CONDITIONS
WO2004028548A3 (en) Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
CY1111654T1 (en) THERAPEUTIC ADMINISTRATION TREATMENT
EP1178796A4 (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2002020619A3 (en) HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
MY122838A (en) Treating allergic and inflammatory conditions
WO2001064031A3 (en) Slpi knockout mice and methods for wound treatment
WO2005056601A3 (en) Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
PT1237562E (en) PROCESS OF PREPARATION OF MYCANYAN EXTRACTS CONTAINING MICANOLIDE AND DIHYDROMICANOLID AND USES IN THE TREATMENT OF PROLIFERATIVE DISEASES
DE60208534D1 (en) USE OF ANTIBODY AGAINST MAG FOR THE TREATMENT OF ISCHEMIC ATTACKS
BG106748A (en) Method and compositions for treating pulmonary diseases
DE60112768D1 (en) TREATMENT OF INFLAMMATORY DISEASES
ATE345121T1 (en) USE OF CONJUGATED LINOLIC ACID TO TREAT THE COMMON COLD

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP